Search academic texts

Information × Registration Number 0225U000926, (0121U112326) , R & D reports Title Developing the algorythm for minimal residual disease diagnostics and immunological rehabilitation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma after antineoplastic program therapy popup.stage_title Розробити алгоритм діагностики МЗХ, який дозволить індивідуалізувати лікувальну тактику у хворих на ХЛЛ/ЛМЛ, а також запропонувати комплекс заходів імунологічної реабілітації та профілактики ускладнень у хворих на ХЛЛ/ЛМЛ, зокрема у пацієнтів з коронавірусною хворобою. Head Vyhovska Yaroslava I., д.мед.н.Masliak Zvenyslava V., д.мед.н. Registration Date 21-01-2025 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description1 Developing the algorythm for minimal residual disease (mrd) diagnostics and immunological rehabilitation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) after antineoplastic program therapy based on the immunophenotypic features of the leukemic and normal peripheral blood lymphocytes as well as parameters of the immune status in these patients. popup.description2  A group of 87 patients treated for chronic lymphocytic leukemia (CLL) were investigated. In 57 (65,5%) of these patients with confirmed complete response minimal residual disease was analyzed and treatment efficacy was evaluated according to its depth. It was found that minimal residual disease (MRD) negative cohort did not have CLL progression, their median progression-free survival was not reached within duration of the study and the only registered death event was related to infection which developed after completion of CLL treatment. Among 14 patients of this MRD-negative group 7 individuals (50%) received modern targeted medications within their last treatment line. We found that all 3 detected CLL progression cases occurred in the cohort of MRD-positive patients. Of note only 1 of these 26 patients received targeted treatment of leukemia. Overall survival rates were confirmed to be higher in MRD-negative group. Part of the CLL patients were found to have decreased levels of IgG below 4,60 g/L which required substitution therapy. Application of the i.v. immunoglobulin G medications enabled bringing its levels to normal within 3 to 6 months. Multicolor flow cytometry panel including 10 types of monoclonal antibodies was developed for detection and evaluation of MRD status in CLL. In complicated cased the panel was recommended to be extended to 15 markers. The MRD diagnostics algorithm was suggested for individualization of the treatment strategy, immunological rehabilitation and prophylaxis of complications in CLL patients which would enable timely detection of disease relapse, have positive impact on the quality of life of the patients and decrease number of immunosuppression-related complications. Product Description popup.authors Horodyska Tetiana O. Danysh Olha Yo. Knysh Nataliia V. Lukavetskyi Les M. Miliashkevych Halyna B. Melnyk Mariia I. Prymak Sofiia V. Thir Hrystyna R. Tsyapka Orest M. Yurchyshak Iryna M. popup.nrat_date 2025-01-21 Close